Jubilant Ingrevia to acquire 40% of Zettaone by 2027

Deal announcement and board approval

Jubilant Ingrevia, a specialty chemicals company, has signed a binding agreement to acquire a 40% strategic stake in Zettaone Technologies India. The company said its Board of Directors has approved the transaction. The purchase consideration is approximately ₹189.2 crore and will be paid entirely in cash. Once the deal closes, Zettaone Technologies will become an associate company of Jubilant Ingrevia. The acquisition is structured as a strategic investment rather than a full takeover.

The company positioned the move as an expansion into Electronics Development and Manufacturing Services (EDMS). It also framed the transaction as a way to deepen its participation across electronics and semiconductors. The announcement comes as Jubilant Ingrevia continues to highlight diversification through adjacent high-value manufacturing segments. The company did not provide a post-deal shareholding structure beyond the 40% stake.

Transaction structure and timeline

Jubilant Ingrevia said the acquisition will be completed in two tranches. The first tranche is targeted for closure by November 2026. The second tranche is expected to close by September 2027. This staggered structure spreads execution over roughly a year, implying the stake build-up will happen in phases rather than all at once.

The company described the agreement as binding, indicating both parties have committed to proceed under defined terms. The disclosure also makes clear that the associate-company status will apply upon completion. Since the deal is cash-funded, the purchase is not linked to equity issuance or debt terms in the information provided. The company has not disclosed any conditions precedent, valuation metrics, or governance rights tied to the strategic stake in the details shared.

Why Jubilant Ingrevia is entering EDMS

Jubilant Ingrevia said the acquisition will strengthen its presence in the EDMS space. It also said the investment will allow it to offer an integrated proposition across electronics and semiconductors. The company linked the transaction to its stated “Pinnacle growth strategy.”

In a joint comment, Shyam S Bhartia, Chairman, and Hari S Bhartia, Co-Chairman and Whole-Time Director, said the proposed investment is aligned with the company’s strategy and provides a platform for its play in EDMS. The company further said the transaction should help it deliver an integrated value proposition in the electronics and semiconductor space. It characterised the expected outcome as long-term and sustainable value creation, while not providing specific financial targets or timelines for synergy realisation.

How Zettaone fits with Jubilant’s CDMO plans

Jubilant Ingrevia said it has been expanding into high-precision semiconductor chemicals through its contract development and manufacturing organisation (CDMO) business. In that context, it highlighted Zettaone’s capabilities in high-speed and high-power PCB design and manufacturing. The company said this expertise will complement its CDMO-led push in semiconductor-related chemicals.

The strategic rationale presented is a broader engagement with customers across the electronics and semiconductor value chain. For Jubilant Ingrevia, the narrative is about moving beyond chemicals into adjacent enabling services and manufacturing capabilities that sit closer to electronics production. For Zettaone, the linkage is through PCB design and manufacturing, which is relevant to electronics hardware and, indirectly, to the ecosystem that uses semiconductor inputs.

Zettaone turnover trend disclosed

Jubilant Ingrevia disclosed Zettaone Technologies’ historical annual turnover for three financial years. The turnover reached ₹98.1 crore in FY26, compared with ₹79.1 crore in FY25 and ₹51.1 crore in FY24. This provides a basic view of the scale of the target and its recent operating trajectory.

No profitability, margin, order book, capacity, or customer concentration details were provided in the information shared. The company also did not disclose whether ₹189.2 crore implies any specific valuation multiple based on turnover. Still, the turnover numbers establish that Zettaone is a relatively smaller entity compared with Jubilant Ingrevia’s consolidated scale.

Key deal facts at a glance

Stock reaction and reported financial snapshot

Jubilant Ingrevia shares closed at ₹729.50 on Tuesday, August 18, down 0.45% or ₹3.30 on the NSE. The move indicates a muted immediate reaction in the session referenced. The company did not link the share-price move to any particular market interpretation in the disclosed details.

The article also carried a brief financial snapshot for Jubilant Ingrevia: Revenue in Q1 FY2027 was reported at ₹1,300 crore and EBITDA at ₹209 crore. These figures provide context on scale, but the company did not provide segmental splits tied to electronics, EDMS, or semiconductor chemicals in the information shared.

Broader acquisition and capital-market context

Separately, Jubilant Ingrevia has also reported other corporate actions in recent periods. The company said it completed the acquisition of a 100% equity stake in Remidex Pharma Private Limited on March 30, 2026 at 6:05 pm IST, following a Share Purchase Agreement announced on March 13, 2026. Another reference in the provided material stated an acquisition of 100% stake in Remidex Pharma for 165 million rupees, which equals ₹16.5 crore.

The broader group context also includes references to stake sales and funding plans around a separate transaction. The provided text cited reporting that the Bhartia family was considering selling small stakes in listed Jubilant firms to part-fund an acquisition of a 40% stake in Hindustan Coca-Cola Beverages, with a reported total consideration of ₹12,500 crore. These references sit outside the Zettaone transaction specifics, but they show parallel capital allocation and funding discussions around the group.

Why the move matters for investors

From the information disclosed, the Zettaone investment is positioned as a structural diversification from specialty chemicals into electronics manufacturing services and the semiconductor value chain. Jubilant Ingrevia has tied it to its CDMO-led expansion into high-precision semiconductor chemicals and to Zettaone’s PCB design and manufacturing expertise. The key measurable disclosures so far are the stake (40%), consideration (₹189.2 crore), the two-tranche schedule through September 2027, and Zettaone’s turnover trend through FY26.

For investors tracking execution, the defined tranche milestones create a timeline that can be monitored through subsequent filings. The associate-company structure indicates Jubilant Ingrevia is taking a significant but non-controlling position, at least based on the stake disclosed. Any further detail on operational collaboration, governance, or financial contribution would likely emerge closer to tranche closures.

Conclusion

Jubilant Ingrevia’s planned ₹189.2 crore cash investment for a 40% stake in Zettaone Technologies is aimed at building a presence in EDMS while linking into the electronics and semiconductor value chain. The deal is expected to close in two tranches, with the first targeted by November 2026 and the second by September 2027. The next clear checkpoints are the tranche-wise closures and any further disclosures on integration plans, governance rights, and the scope of the combined electronics and semiconductor offering.